We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Immundiagnostik AG

Immundiagnostik AG s a globally operating diagnostics company that focuses on the development and production of innov... read more Featured Products: More products

Download Mobile App





Immundiagnostik AG Presents New PCR Test MutaPLEX RespiraScreen4_Diff_seqc at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022

Immundiagnostik AG (Bensheim, Germany) is presenting its new PCR test MutaPLEX RespiraScreen4_Diff_seqc for the first time at this year's MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany. More...

The test kit developed by Immundiagnostik is a further development of the existing products MutaPLEX RespiraScreen1 and MutaPLEX Coronavirus and represents a comprehensive real-time PCR diagnostic tool that efficiently, conveniently and reliably masters the expected respiratory diagnostic challenge in every new winter season.

The MutaPLEX RespiraScreen4_Diff_seqc real-time PCR test can be used to detect three different respiratory pathogens highly efficiently in just one approach: Coronavirus, Influenza Virus and RSV=Respiratory Syntial Virus. The innovative combination of two basic PCR techniques, namely qualitative amplification followed by melting curve analysis, allows the respective pathogens to be detected and differentiated in the same experiment. This means that in case of positivity (i.e. in the first step "amplification") in the case of coronavirus two different CoV-2 genes (S=Spike & E=Envelope) are specifically detected and in the case of influenza and RSV respectively the subtypes A and subtypes B are specifically detected. In all three cases, the distinction is made in the second step of the "melting curve analysis".

In addition, the entire diagnostic process is rounded off by the verification of the original sample collection by means of the detection of a human housekeeping gene. In times of pandemic coronalage, which has been ongoing for more than two years now, this is still essential, as the collection of respiratory pathogens from the nasal or oral/pharyngeal region may be suboptimal, resulting in inefficient sample collection. In these rare but not excludable cases, false-negative results in subsequent PCR diagnostics in the laboratory/testing center are inevitably the consequence.

Amplification of the human housekeeping gene on a separate detection channel of the real-time PCR instrument used provides an excellent means of controlling this situation. Detection of the human housekeeping gene provides assurance not only to the processing laboratory, but also to the specimen-submitting physician (and, not least, to the specimen-taking staff of the testing center) that the clinical source material collected and transferred to the laboratory met the requirements of correct specimen collection via swab smear. If the household gene amplification is strongly reduced or missing, the PCR result is not valid and a diagnosis of the patient sample is not possible. As a consequence, a new sample must be requested.

Related Links:
Immundiagnostik AG


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Whole Blood Control
Lyphochek Whole Blood Control
New
Silver Member
Luteinizing Hormone Test
Luteinizing Hormone (LH) Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.